PRRT in Hindgut and Cancer of Unknown Primary NEN Abstract #2290

Introduction: There are limited data regarding PRRT in hindgut and CUP (cancer of unknown primary).
Aim(s): To compare the long term effectiveness of PRRT (90Y or 177Lu DOTATATE), based on OS and PFS, in patients with extensive, progressive, non-resectable NEN hindgut and CUP origin.
Materials and methods: 22 patients, hindgut, n=8 and CUP n=14. All treated with PRRT; 177Lu (n=8); 90Y (n=14). Clinical responses were assessed 6 weeks after PRRT and then at the 3-month intervals. The clinical efficacy determine evaluating performance status (PS) and reduction of clinical symptoms. OS and PFS were assessed using Kaplan –Meier. Radiological response was classified according to RECIST 1.0.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD, PhD Agnieszka Kolasińska-Ćwikła
Keywords: NENs, PRRT, Hindgut, CUP

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2060 Peptide Receptor Radionuclide Therapy (PRRT) in 35 Patients with Metastatic Neuroendocrine Neoplasms (NENs): Overall Response and Toxicity
Introduction: Metastatic or inoperable NeuroEndocrine Neoplasms (NENs) are unresponsive to chemotherapy and targeted therapies. An emerging option is PRRT.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Theodora Liotsou
Keywords: NENs, PRRT
#1568 Neuroendocrine Neoplasm of the Colon and Rectum, Pathological and Clinical Characteristics, Based on pTNM WHO 2010 Classification
Introduction: Large bowel neuroendocrine neoplasms (NENs)
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Jaroslaw Cwikła
#1894 Survival Analysis after i.a. 90Y-DOTATATE PRRT, in Patients with Non-Resectable, Advanced, Progressive, Liver-Dominant Neuroendocrine Neoplasms
Introduction: A
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: MD, PhD Miroslaw L Nowicki
#2268 Efficacy of Octreotide LAR in Treatment of Naive Patients with Advanced, Non-Resectable Well and Moderate Differentiated Pancreatic Neuroendocrine Neoplasms (p-NENs)
Introduction: SSA are the first line therapy in well differentiated pNET
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Md, PhD Agnieszka Kolasińska-Ćwikla
#1228 Measurement of Blood Gene Transcripts Defines PRRT Therapeutic Efficacy
Introduction: PRRT is an effective therapy for NETs since the majority over-express SSRs. Typically, well or moderately differentiated NETs (G1/G2) are treated. Imaging and CgA are used to evaluate response but both RECIST criteria and CgA have limitations.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Bodei L, Paganelli G, Kidd M, Severi S, ...